SPP1 rs9138 variant contributes to the severity of radiological damage in anti-citrullinated protein autoantibody-negative rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 73, Issue 10, 2014, Pages 1840-1843

  Juge, Pierre Antoine ^a   Van Steenbergen, Hanna W ^b   Constantin, Arnaud ^c   Tobon, Gabriel J ^d   Schaeverbeke, Thierry ^e   Gazal, Steven ^a   Combe, Bernard ^f   Devauchelle Pensec, Valérie ^d   Nigon, Delphine ^c   Van Der Helm Van Mil, Annette H M ^b   Dieude, Philippe ^a,g  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e HÔPITAL PELLEGRIN   (France)

^f MONTPELLIER UNIVERSITY HOSPITAL   (France)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; OSTEOPONTIN; SPP1 PROTEIN, HUMAN;

ADULT; AGED; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; FEMALE; FOOT; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; GENOTYPE; HAND JOINT; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; RADIOGRAPHY; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FOOT JOINTS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAND JOINTS; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PEPTIDES, CYCLIC;

EID: 84925231407     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205539     Document Type: Article

References (20)

1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
2. van der Woude D, Houwing-Duistermaat JJ, Toes RE, et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009;60:916-23.
3. Gazal S, Sacre K, Allanore Y, et al. Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. Ann Rheum Dis 2014. Published Online First: 21 Jan 2014. doi:10.1136/annrheumdis-2013-204581
4. Padyukov L, Seielstad M, Ong RT, et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011;70:259-65.
5. van der Helm-van Mil AH, Huizinga TW, de Vries RR, et al. Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. Arthritis Rheum 2007;56:1728-35.
6. Knevel R, Grondal G, Huizinga TW, et al. Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2012;71:707-9.
7. de Rooy DP, Yeremenko NG, Wilson AG, et al. Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis 2013;72:769-75.
8. de Rooy DP, Zhernakova A, Tsonaka R, et al. A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 2014;73:1163-9.
9. Knevel R, de Rooy DP, Zhernakova A, et al. Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 2013;65:1684-93.
10. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 1998;30-31:92-102.
12. Combe B, Benessiano J, Berenbaum F, et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74:440-5.
13. de Rooy DP, van der Linden MP, Knevel R, et al. Predicting arthritis outcomes: what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011;50:93-100.
14. van der Heijde D, Boers M, Lassere M. Methodological issues in radiographic scoring methods in rheumatoid arthritis. J Rheumatol 1999;26:726-30.
15. Knevel R, Tsonaka R, le Cessie S, et al. Comparison of methodologies for analysing the progression of joint destruction in rheumatoid arthritis. Scand J Rheumatol 2013;42:182-9.
16. Tobon G, Saraux A, Lukas C, et al. First-year radiographic progression as a predictor of further progression in early arthritis: results of a large national French cohort. Arthritis Care Res (Hoboken) 2013;65:1907-15.
17. D'Alfonso S, Barizzone N, Giordano M, et al. Two single-nucleotide polymorphisms in the 50 and 30 ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2005;52:539-47.
18. Yumoto K, Ishijima M, Rittling SR, et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA 2002;99:4556-61.
19. Jacobs JP, Pettit AR, Shinohara ML, et al. Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis. Arthritis Rheum 2004;50:2685-94.
20. Boumans MJ, Houbiers JG, Verschueren P, et al. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann Rheum Dis 2012;71:180-5.